Clinical Trial Detail

NCT ID NCT01485861
Title Study of GDC-0068 Or GDC-0980 With Abiraterone Acetate Versus Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy
Recruitment Active, not recruiting
Gender male
Phase Phase II
Variant Requirements no
Sponsors Genentech, Inc.
Indications

prostate adenocarcinoma

Therapies

GDC-0980

Abiraterone

Ipatasertib

Age Groups: adult

No variant requirements are available.